AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06579573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate will be orally administered once daily.
Study NCT05403008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconomer improved
Description: Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
Study NCT05403008 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zirconomer improved
Description: Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opevesostat
Description: Administered orally
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Administered orally
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Administered orally
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Administered orally or IM as a rescue medication
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered orally
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally
Study NCT06136624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally as rescue medication
Study NCT06111690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training (BFRT)
Description: Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
Study NCT06637319 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound scan of blood vessels where front of neck access vertical incision would take place in a cant intubate cant oxygenate scenario
Study NCT06240442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted exercise
Description: Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
Study NCT06240442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed exercise
Description: Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
Study NCT05909332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivascular therapy
Description: BP102 (anti VEGFR)
Study NCT05909332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: ddEC-P
Study NCT05909332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: ddEC-P
Study NCT04997369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
Study NCT05521516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge
Description: Application of 5 days of percutaneous auricular neuromodulation with NSS-2 Bridge device
Study NCT05521516 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Application of 5 days of a nonfunctional sham device
Study NCT06502990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Study NCT04747314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant
Description: The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change.
Study NCT04747314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Fear Avoidance Rehabilitation
Description: The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
Study NCT04783155 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: POWERBreathe Plus®
Description: Commercially available pressure-threshold device
Study NCT04783155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERBreathe Plus®
Description: Commercially available pressure-threshold device
Study NCT04783155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary rehabilitation post lung transplant
Description: Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
Study NCT04783155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation post lung transplant
Description: Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
Study NCT05326776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitocin
Description: At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
Study NCT05642715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX+
Description: All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
Study NCT05642715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EX+
Description: All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
Study NCT05642715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
Study NCT05642715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
Study NCT05642715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HR
Description: Participants allocated to the EX+/HR arm will be offered: 30-minute video urging smokers who cannot or will not quit to cut down on cigarettes, and also to control their risk for lung cancer and cardio or cerebrovascular disease by undergoing low-dose CT screening for lung cancer (for those meeting prespecified criteria), and referral to Cardiometabolic Clinic (for those meeting prespecified criteria).
Study NCT05642715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Participants allocated to the EX+/TAU arm will be offered: Medical treatment as usual from their regular providers after completing Stage 1 of the study
Study NCT05394818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
Study NCT06643195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ImmediateAllogeneic Hematopoietic Stem Cell Transplantation
Description: patients proceeded to allogeneic HSCT as soon as possible. Patients were allowed to receive low-dose chemotherapy that is not intended for the purpose of achieving a second remission.
Study NCT06643195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retreatment
Description: Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
Study NCT05513716 — intervention group
Intervention type: OTHER
Intervention: Retrospective tissue sample analysis
Description: Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
Study NCT05144763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePOCT+
Description: ePOCT+ is an electronic clinical decision support algorithm
Study NCT05867667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehab
Description: Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
Study NCT04066348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: To treat blast or noise induced tinnitus
Study NCT04066348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT04948749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent implantation
Description: The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
Study NCT04948749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggressive medical treatment
Description: Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
Study NCT04948749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk factor management
Description: Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
Study NCT04948749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk factor management
Description: Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
Study NCT04948749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
Study NCT05300711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery
Description: Colorectal surgery as indicated by attending surgeon.
Study NCT06240169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with MTA in AGEI
Description: DPC using MTA in 18-40 years
Study NCT06240169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with BD in AGEI
Description: DPC using BD in 18-40 years
Study NCT06240169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with MTA in AGEII
Description: DPC using MTA in 41-60Years
Study NCT06240169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with BD in AGEII
Description: DPC using BD in 41-60Years
Study NCT06370689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes
Study NCT04369547 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
Study NCT04369547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
Study NCT04369547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast 250mcg
Study NCT04369547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo capsule matched to roflumilast capsule
Study NCT03897049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans Women Connected
Description: The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
Study NCT03897049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health App
Description: The control group will download a mobile app that addresses COVID and provides COVID resources.
Study NCT05463289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of Care Autonomous AI diabetic retinopathy exam
Description: Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
Study NCT06032195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: heart will preserved in and will be treated with Custodiol-N solution
Study NCT04985747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polished palatal surface
Description: Polishing of the anterior palatal surface using a polisher
Study NCT04985747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roughened palatal surface
Description: Roughening of the anterior palatal surface using a sandblaster
Study NCT04985747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opened palatal surface
Description: Opening of the anterior palatal surface using acrylic bur
Study NCT06032195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: heart will preserved in and will be treated with Custodiol solution
Study NCT06011525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard cold cap
Description: Standard cold-cap applied throughout anthracycline- and taxane-based chemotherapy treatment.~This device will be supplemented by a compressive bandage in order to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the efficacy of the device.
Study NCT06011525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp-cooling technique
Description: Scalp-cooling technique applied throughout anthracycline- and taxane-based chemotherapy treatment
Study NCT06538727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation Treatment - Scapular Release
Description: First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
Study NCT05131685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction
Description: closed reduction under conscious sedation followed by casting
Study NCT05131685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: immobilization in cast without reduction
Study NCT04623099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
Study NCT04623099 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
Study NCT06461962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Peer-facilitated referral to a local primary care provider to follow-up their screening results.
Study NCT06461962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Cardiology
Description: Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer~Referral for a locally performed testing including echocardiogram~Transitional care management facilitated by a remote nurse care manager and the peer
Study NCT06294639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: esketamine will be given intravenously
Study NCT05804526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC88
Description: 1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
Study NCT05804526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
Study NCT05478720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose
Study NCT05478720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous dose of saline
Study NCT05478720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
Study NCT04781530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)
Description: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
Study NCT04789668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04789668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Given PO
Study NCT04789668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06544733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720
Description: Tablets administered orally without regard to food
Study NCT06544733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4182
Description: Tablets administered orally without regard to food
Study NCT06544733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match BVY
Description: Tablets administered orally without regard to food
Study NCT06544733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Tablets administered orally without regard to food
Study NCT06544733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food
Study NCT06544733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Match GS1720/GS-4182 FDC
Description: Tablets administered orally without regard to food